Marco Filice is an associate researcher at the Dept. of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, Complutense University of Madrid (UCM, Spain), head of the Nanobiotechnology Group (UCM) and researcher at the Spanish Biomedical Network of Research in Respiratory Diseases (CIBERES) depending of the National Institute of Health Carlos III. He graduated in Pharmaceutical Chemistry and Technology and obtained a PhD in Pharmaceutical Chemistry from the University of Pavia, Italy. Before joining the UCM, he was a researcher firstly at the Institute of Catalysis (ICP-CSIC) and then at the Institute of Material Science (ICMM-CSIC) both belonging to the Spanish National Research Council. As Principal Scientist responsible for the development of novel ultrasensitive POC diagnostics, he joined the AlphaSIP molecular biosensing Company (Spain). After that, he joined the Advanced Imaging Unit belonging to Spanish Cardiovascular Research Center (CNIC) of Madrid. His research work is mainly focused on the multidisciplinary-based design and creation of nanosized-materials/biomacromolecules artificial hybrids showing highly improved or de novo biological properties. These highly engineered chimers are achieved by integrating a wide set of different disciplines such as surface and colloids chemistry, nanotechnology, bioorganic and bioinorganic chemistry, enzymology, bioinformatics, biocatalysis, site-specific modification, oriented immobilization of biomacromolecules, molecular imaging or biochemistry.

The as prepared artificial nanobiohybrids showed a wide application scope mainly in advanced synthesis and catalysis, development of novel ultrasensitive molecular diagnostic and nanomedicine (theranosis of cardiovascular, pulmonary, cancer and immune-based diseases).